Pharmafile Logo

Extraordinary lives: advancing change in rare diseases (Part 2)

In support of Rare Disease Day, we’re excited to launch part 2 of our video series; Extraordinary lives: advancing change in rare diseases.Why is raising awareness of rare diseases so important?Because 300 million people worldwide are living with a rare disease. This means that, collectively, the number of people living with a rare disease is equivalent to the population of the world’s third-largest country (USA).While we have come a long way since the inception of Rare Disease Day, there’s still plenty of work to do.Part 2 of this series focuses on important topics including the role of technology and the opportunities it presents for the rare disease community. The panel also hold captivating insights on how the pandemic has impacted the use of related digital technologies, the role of gene therapy, the major challenges and successes for pharma companies in supporting the rare disease community over the last 13 years, and much, much more.If you’d like to know more about the work we do in rare diseases or would like advice on any healthcare communication challenges please get in touch with Clare Reynolds on LinkedIn or by email: clare.reynolds@wearelucidgroup.comAbout Lucid GroupFounded in 2007, Lucid Group is a global multi-capability healthcare consultancy with core expertise in medical strategy, healthcare communications, creative and brand strategy, motion, digital and technology, behaviour change, metrics, and data analytics.  We partner with the pharma and biotech industry, delivering life-transforming value with connected capabilities to create pioneering solutions that change behaviour, improve clinical practice and advance health outcomes.  Transforming lives. Always.

This content was provided by Lucid Group Communications Limited

Company Details

 Latest Content from  Lucid Group Communications Limited 

Lucid celebrate big wins at PMEA 2015

Success for Lucid at PMEA 2015

Lucid invests in their Futures programme with a new hire

Lucid Group continues their expansion

Janus kinase inhibitors are amongst the most read abstracts at the American College of Rheumatology 2015

Rheumatologists eagerly await trial data for Janus kinase inhibitors

Making a difference to patients with IBD

Changing lives with medical education

Lucid Group showcases new KOL identification and mapping tool

Advancing Expert identification with digital new tool from Lucid Group

Lucid CEO discusses his inspiration and passion for changing patients’ lives

Changing patients' lives with innovative methodologies in medical education

Lucid Group starts new trend for CME in IBD education

A tailored educational event in IBD